Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma

Summary Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight,...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2008-11, Vol.143 (3), p.374-377
Main Authors: Vari, F., Munster, D. J., Hsu, J. L., Rossetti, T. R., Mahler, S. M., Gray, P. P., Turtle, C. J., Prue, R. L., Hart, D. N. J.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - isolation & purification
Antigen Presentation - immunology
Antigens, Differentiation - immunology
Antigens, Neoplasm - immunology
Biological and medical sciences
Biotinylation
blood dendritic cells
cancer vaccine
Cancer Vaccines - therapeutic use
Cells, Cultured
Cytotoxicity, Immunologic
Dendritic Cells - transplantation
Hematologic and hematopoietic diseases
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
immunomagnetic separation
Immunomagnetic Separation - methods
Immunopathology
immunotherapy
Leukapheresis
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
multiple myeloma
Multiple Myeloma - immunology
Multiple Myeloma - therapy
T-Lymphocytes, Cytotoxic - immunology
Vaccination - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF‐56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2008.07346.x